Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons

Neurobiology of Disease

Volumn 85, Issue , 2016, Pages 1-10

  Rodríguez Martín, Teresa ^a   Pooler, Amy M ^a,c   Lau, Dawn H W ^a   Mórotz, Gábor M ^a   De Vos, Kurt J ^a,d   Gilley, Jonathan ^b   Coleman, Michael P ^b   Hanger, Diane P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BABRAHAM INSTITUTE   (United Kingdom)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Axonal transport; Dementia; Membrane; Mitochondria; Phosphorylation; Tau

Indexed keywords

TAU PROTEIN; MAPT PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CELL; CELL COUNT; CELL KINETICS; CELL MEMBRANE; CELL SURVIVAL; CELL TRANSPORT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; EMBRYO; MITOCHONDRION; MOUSE; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; ANIMAL; AXON; BRAIN CORTEX; C57BL MOUSE; CELL CULTURE; CYTOSOL; GENETICS; METABOLISM; MICROTUBULE; MUTATION; PATHOLOGY; PHOSPHORYLATION; RAT; TRANSGENIC MOUSE;

ANIMALS; AXONS; CELL MEMBRANE; CELLS, CULTURED; CEREBRAL CORTEX; CYTOSOL; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROTUBULES; MITOCHONDRIA; MUTATION; PHOSPHORYLATION; RATS; TAU PROTEINS;

EID: 84945209005     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.10.007     Document Type: Article

References (50)

1. Allen B., et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 2002, 22:9340-9351.
2. Amadoro G., et al. AD-linked, toxic NH2 human tau affects the quality control of mitochondria in neurons. Neurobiol. Dis. 2014, 62:489-507.
3. Andreadis A., et al. Structure and novel exons of the human tau gene. Biochemistry 1992, 31:10626-10633.
4. Andrews S., et al. Difference tracker: ImageJ plugins for fully automated analysis of multiple axonal transport parameters. J. Neurosci. Methods 2010, 193:281-287.
5. Ballatore C., et al. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
6. Bramblett G.T., et al. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993, 10:1089-1099.
7. Busciglio J., et al. Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995, 14:879-888.
8. Butner K.A., Kirschner M.W. Tau protein binds to microtubules through a flexible array of distributed weak sites. J. Cell Biol. 1991, 115:717-730.
9. Cuchillo-Ibanez I., et al. Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J. 2008, 22:3186-3195.
10. David D.C., et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 2005, 280:23802-23814.
11. Dayanandan R., et al. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett. 1999, 446:228-232.
12. De Vos K.J., et al. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 2008, 31:151-173.
13. Denk F., Wade-Martins R. Knock-out and transgenic mouse models of tauopathies. Neurobiol. Aging 2009, 30:1-13.
14. Deshpande A., et al. Tau isoform expression and regulation in human cortical neurons. FASEB J. 2008, 22:2357-2367.
15. Ding H., et al. Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J. Biol. Chem. 2006, 281:19107-19114.
16. D'Souza I., et al. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5598-5603.
17. Eckert A., et al. March separate, strike together - Role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease. Biochim. Biophys. Acta 2013, 1842:1258-1266.
18. Exner N., et al. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012, 31:3038-3062.
19. Gallo J.M., et al. RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies. Cell Mol. Life Sci. 2007, 64:1701-1714.
20. Gilley J., et al. Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse. Neurobiol. Aging 2012, 33:621.e1-621.e15.
21. Goedert M., et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989, 3:519-526.
22. Goedert M., et al. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates ç protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J. Neurochem. 1995, 65:2804-2807.
23. Gong C.X., et al. Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 1994, 61:765-772.
24. Grover A., et al. 5' splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J. Biol. Chem. 1999, 274:15134-15143.
25. Hanger D.P., et al. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 1992, 147:58-62.
26. Hanger D.P., et al. The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies. FEBS Lett. 2002, 531:538-542.
27. Hernandez F., et al. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J. Neurochem. 2002, 83:1529-1533.
28. Hernandez F., et al. Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J. Biol. Chem. 2004, 279:3801-3806.
29. Hong M., et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998, 282:1914-1917.
30. Hutton M., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
31. Kim-Han J.S., et al. The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J. Neurosci. 2011, 31:7212-7221.
32. Lee G., Rook S.L. Expression of tau protein in non-neuronal cells: microtubule binding and stabilization. J. Cell Sci. 1992, 102:227-237.
33. Lewis J., et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000, 25:402-405.
34. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
35. Liu F., et al. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 2005, 22:1942-1950.
36. Magrane J., et al. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum. Mol. Genet. 2014, 23:1413-1424.
37. Manczak M., Reddy P.H. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum. Mol. Genet. 2012, 21:2538-2547.
38. Manser C., et al. Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo. Oncogene 2012, 31:2773-2782.
39. Morotz G.M., et al. Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria. Hum. Mol. Genet. 2012, 21:1979-1988.
40. Noble W., et al. Transgenic mouse models of tauopathy in drug discovery. CNS Neurol. Disord. Drug Targets 2010, 9:403-428.
41. Pooler A.M., et al. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol. Aging 2012, 33:431.e27-431.e38.
42. Pooler A.M., et al. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013, 14:389-394.
43. Poorkaj P., et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998, 43:815-825.
44. Rodriguez-Martin T., et al. Tau phosphorylation affects its axonal transport and degradation. Neurobiol. Aging 2013, 34:2146-2157.
45. Santacruz K., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
46. Schulz K.L., et al. A new link to mitochondrial impairment in tauopathies. Mol. Neurobiol. 2012, 46:205-216.
47. Shao C.Y., et al. Distinct functions of nuclear distribution proteins LIS1, Ndel1 and NudCL in regulating axonal mitochondrial transport. Traffic 2013, 14:785-797.
48. Spillantini M.G., et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7737-7741.
49. Terwel D., et al. Changed conformation of mutant tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of tau-4R/2N transgenic mice. J. Biol. Chem. 2005, 280:3963-3973.
50. Yoshiyama Y., et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.